Starpharma today announced that CEO Dr Jackie Fairley will present at the 7^th Annual Biotech Showcase^TM conference in San Francisco this week. The Biotech Showcase^TM coincides with the Annual J.P. Morgan Healthcare Conference, which Starpharma is also attending.

Starpharma today announced that the planned launch timing of the VivaGel^® condom in Japan would be delayed following a review of the specific category of medical device classification by the Japanese regulatory authorities.

Starpharma today announced the completion of the regulatory requirements to allow for marketing of the VivaGel^® condom in New Zealand under the brand Lifestyles^® Dual Protect™.

Starpharma today announced that the State Intellectual Property Office of China has agreed to grant a formulation patent for Priostar^® dendrimers with agrochemicals, including with glyphosate. This will further strengthen and expand Starpharma’s patent portfolio for the use of its proprietary dendrimers in agrochemical products.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2014.

Starpharma today announced it has raised a total of approximately $21.5 million following the closing of its Share Purchase Plan (SPP) on Wednesday 29 October 2014. The Company raised approximately $3.5 million from existing eligible shareholders through the SPP. The SPP followed the Company’s recent $18 million share placement to sophisticated and institutional investors, which was significantly oversubscribed. 

Starpharma today announced it has received the anticipated $4.2M of R&D tax incentive refund relating to FY14 expenditures.  

Starpharma is pleased to announce that the Company has been notified by its commercial partner, Ansell (ASX:ANN), that the VivaGel^® condom is now available for purchase from Woolworths stores in Australia under Ansell’s brand, LifeStyles^® Dual Protect™. 

Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).

Starpharma advises that it has extended the closing date of its share purchase plan (SPP) following the release today of preliminary positive DEP™ docetaxel pharmacokinetic (PK) findings from its Phase I clinical trial.